UEG Week 2022

Treat-to-target still alive?

Is IL-23 the super target?

Treat-to-target with ustekinumab - why didn't it work?

The benefit of early intervention in CD

What is new in anti-TNFα therapy?

Personalized therapy - de-escalation strategies

T reg - a new therapeutic target in IBD?

Enhanced treatment algorithm for the management of CD

TYK2 Deucravacitinib in ulcerative colitis

You can still treat severe biofailure in CD

Small molecules in crohn's disease

Thinking out of the box - co-medication of the elderly

Pharmacokinetics of ustekinumab in the STARDUST trial

Treating the patient as a whole

Anti-IL-23 monoclonal antibodies: is it better to…

Treat-to-target strategy is superior to conventional…

Explosion of new drugs

Oral anti-integrin therapy in IBD - new data, new…

Combination therapy: week 38 efficacy and safety data…

VEGA - the story continues

No matter what you use - treat early!

Once more a shocking message: be aware of steroids!

Postoperative monitoring matters!

Thinking out of the box - Einfluss der…

Terapia di combinazione: efficacia e sicurezza a 38…

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα…

Treating the patient as a whole

Anticorps anti-IL-23: est-il préferabble de cibler…

VEGA - l'histoire continue

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Was tun nach der Operation?

Small molecules nel morbo di crohn

Doustna terapia antyintegrynowa - nowe dane, nowe…

TYK2 Deucravacitinib bei Colitis ulcerosa

Una strategia “Treat-to-target” è superiore rispetto…

T reg - nowy cel terapeutyczny w IBD?

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά…

Les résultats à long terme d'une combIothérapie

Update on JAK inhibition in UC

S1P receptor modulators

1st JAK inhibitor in CD - a game changer?

Estrasimod in moderate to severe active UC

The 1st JAKi in CD

Upadacitinib maintenance therapy - final results from…

The era of small molecules

Ozanimod works in young and old UC patient

Upadacitinib - induction therapy in CD

Histological response and remission induced by…

Risankizumab in refractory CD patients

Persistance on therapy and real-world clinical…

JAK-inhibition

Selective IL-23 blockade

VEGA & LUCENT studies

The area of small molecules

Upadacitinib - Induktionsdaten bei CD

Risankizumab dans la maladie de Crohn réfractaire

Persistenza in terapia ed efficaci clinica di…

Selective IL-23 Blockade

VEGA & LUCENT studi clinici

Risultati finali di efficacia e sicurezza a 52…

Treating the elderly - closer surveillance and the…

Urgency - putting the focus on an important endpoint!

Filgotinib is efficacious in inducing and maintaining…

Urgency matters!

Patient reported outcomes in IBD

Neue Studienendpunkte in IBD

Explosion of Spanish contributions

Wo kommt die Crohn-Genetik her? Die Historie der IL-23…